. Author manuscript; available in PMC: 2010 Jun 15.

Published in final edited form as: Lett Drug Des Discov. 2009 Mar;6(2):133–138. doi: 10.2174/157018009787582624

Table 1.

GI₅₀, TGI and LC₅₀ values (μM) for conjugates 10, 11 and 13 for 5-dose assay in the full NCI-7-cell line panels (Data obtained from NCI's in vitro tumor-cell screen).

Breast cancer cell (Type)	GI₅₀ (μM) of Conjugate			TGI (μM) of conjugate			LC₅₀ (μM) of conjugate
Breast cancer cell (Type)	10	11	13	10	11	13	10	11	13
MCF-7 (Invasive ductal carcinoma)	100	3.63	12.6	100	15.0	42.5	100	100	100
NCI/ADR-RES (Adenocarcinoma)	29.5	26.2	12.4	100	100	100	100	100	100
MDA-MB-231/ATCC (Adenocarcinoma)	100	2.80	4.85	100	14.4	18.4	80.5	80.5	48.1
HS 578T (Invasive ductal carcinoma)	27.6	17.7	29.4	100	100	87.5	100	100	100
MDA-MB-435 (Invasive ductal carcinoma)	1.22	5.40	11.4	100	100	100	100	100	100
BT-549 (Invasive ductal carcinoma)	4.53	27.0	12.1	100	100	41.2	100	100	100
T-47D (Invasive ductal carcinoma)	100	32.0	8.45	100	100	38.2	100	100	100

GI₅₀ = growth inhibition by 50%; TGI = 100% (total) growth inhibition, signifying a cytostatic effect; LC₅₀ = 50% cell kill or lethal concentration, signifying a cytotoxic effect.